Weikun Xia

Weikun Xia

Auto-generated profile, based on publicly available information

Weikun Xia

Krantz Family Center for Cancer Research, Massachusetts General Hospital, Mass General Brigham Cancer Institute and Harvard Medical School, Charlestown, Massachusetts

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 July 2019 in Science
Verified
Journal Article
Closed access
PDF file
WXWeikun Xia
Weikun Xia
XJXu Jiawei
Xu Jiawei
GYGuang Yu
Guang Yu
YGYao Guidong
Yao Guidong
KXKai Xu
Kai Xu
YSYing-Pu Sun
Ying-Pu Sun
Epigenetics of human embryonic development: Substantial epigenetic reprogramming occurs in mammalian early development. Xia et al. investigated the reprogramming dynamics of three key histone modifications in human early embryonic development. The reprogramming in humans is highly species-specific and different than that in mice. A globally permissive chromatin state connects parental and zygotic epigenomes during maternal-to-zygotic transition. Inner-cell mass-specific, but not trophectoderm-specific, genes are asymmetrically patterned by a histone mark during early lineage segregation. Science , this issue p. 353

28 October 2020 in Nature
Verified
Journal Article
Closed access
PDF file
BLBofeng Liu
Bofeng Liu
QXQianhua Xu
Qianhua Xu
QWQiujun Wang
Qiujun Wang
SFSu Feng
Su Feng
FLFangnong Lai
Fangnong Lai
WXWei Xie
Wei Xie

20 July 2020 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
QWQiujun Wang
Qiujun Wang
GYGuang Yu
Guang Yu
XMXuan Ming
Xuan Ming
WXWeikun Xia
Weikun Xia
XXXiguang Xu
Xiguang Xu
WXWei Xie
Wei Xie

26 November 2021 in Science Advances
Verified
Journal Article
Open access
XLXukun Lu
Xukun Lu
YZYu Zhang
Yu Zhang
LWLijuan Wang
Lijuan Wang
LWLeyun Wang
Leyun Wang
HWHuili Wang
Huili Wang
WXWei Xie
Wei Xie
Evolutionary analyses reveal conservation and divergence of epigenetic transition during early development across mammals.

24 December 2021 in Science Advances
Verified
Journal Article
Open access
XWXiaotong Wu
Xiaotong Wu
HZHongmei Zhang
Hongmei Zhang
BZBingjie Zhang
Bingjie Zhang
YZYu Zhang
Yu Zhang
QWQiuyan Wang
Qiuyan Wang
WXWei Xie
Wei Xie
Enhancer dememorization resets developmental clock and may unify epigenetic reprogramming modes in mammals and nonmammals.

14 January 2026 in Cancer Discovery
Verified
Journal Article
Open access
AMAvanish Mishra
Avanish Mishra
CMCatherine B. Meador
Catherine B. Meador
KKKruthika Kikkeri
Kruthika Kikkeri
QCQuinn Cunneely
Quinn Cunneely
MLMaoxuan Lin
Maoxuan Lin
DHDaniel A. Haber
Daniel A. Haber
The bispecific antibody tarlatamab recruits T cells to cancers expressing the neuroendocrine epitope delta-like ligand 3 (DLL3). Tarlatamab is effective in small cell lung cancer (SCLC), but clinical outcomes vary, and no biomarkers enable patient selection. Single-cell RNA sequencing of SCLC biopsies identifies heterogeneity in DLL3 expression, and analysis of circulating tumor cells (CTC) distinguishes individual patients as predominantly DLL3Pos or DLL3Low. In a prospective cohort of 20 patients, pretreatment DLL3 expression on CTCs predicts tarlatamab clinical benefit (85% sensitivity and 100% specificity). Necrotic CTC clusters in blood accompany treatment-induced tumor lysis. Acquired resistance to tarlatamab is associated in some cases with loss of DLL3 expression but persistence of other targetable neuroendocrine epitopes; in other patients, DLL3 is retained on CTCs but accompanied by systemic markers of T-cell dysfunction. Quantitation of DLL3-positive CTCs identifies patients likely to benefit from tarlatamab, and longitudinal monitoring may guide therapeutic decision-making at the time of acquired resistance. Significance: CTCs are abundant in SCLC, allowing noninvasive quantitation of epitopes targeted by immune therapies. Patients with at least 25% DLL3-positive CTCs derive clinical benefit from a bispecific antibody targeting this epitope; those with a lower fraction rarely respond. CTC scoring may thus enable stratification of patients for antibody-mediated therapeutics.